Daily, oral FMT for long-term maintenance therapy in ulcerative colitis: results of a single-center, prospective, randomized pilot study

Table 3 Changes in clinical, endoscopic, and histologic evidence of disease by subject

	Study code	Age	Sex	Extent of disease	Duration of disease (yrs)	Maintenance therapy	BMI	Change in total Mayo score	Change in endoscopic UCEIS score	Change in endoscopic Mayo score	Change in histologic score	Change in fecal calprotectin (mcg/g)	Change in total IBDQ score
FMT	E	46	F	Pan-colitis	5.5	Mesalamine	20.9	− 7	− 2	0	− 3	− 285	92
	W	35	M	Pan-colitis	7.5	Vedolizumab	27.8	− 3	− 1	0	− 1.3	− 189	47
	F	20	M	Pan-colitis	3.8	Mesalamine	25	− 1	− 1	0	− 2	− 164	16
	A	65	F	L-sided	26.2	Mesalamine	20.9	3	0	1	− 1.2	? = > 375	8
	N	44	M	Pan-colitis	0.2	Sulfasalazine	25.6	1	− 3	0	0.9	> 1000 = > > 1000	59
	P	38	M	Pan-colitis	10.2	Mercaptopurine	25.2	− 3	2	− 1	0	− 42	32
Placebo	B	68	M	Pan-colitis	4.4	Mesalamine	28.8	− 2	− 1	0	0.8	− 132	21
	G	58	M	L-sided	27.8	Mesalamine	26.9	1	0	0	− 2	4	32
	Y	65	M	L-sided	0.4	Mesalamine	36.15	0	0	0	0	74	4
	V	47	F	Pan-colitis	8.8	Adalimumab	29.2	− 1	0	0	0	27	35
	T	31	F	Pan-colitis	0.8	Mesalamine	29.1	0	− 1	0	0	− 137	32
	I	40	F	Pan-colitis	16.3	Mesalamine	25	Dropped out due to worsening disease activity

IBDQ, Inflammatory Bowel Disease Questionnaire; L-Sides, left-sided disease; BMI, Body Mass Index; yrs, years; wks, weeks
^Ulcerative Colitis Endoscopic Index of Severity
*Geboes Score

ISSN: 1471-230X